[Supportive therapy with xenogenous peptides in patients with metastatic breast cancer undergoing aggressive chemotherapy (modified AC-protocol): a prospective, randomized double-blind study].
Lange
O F
OF
Robert-Janker-Klinik, Bonn.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004311:Double-Blind Method; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy; D010455:Peptides / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation
D010455:Peptides; D004317:Doxorubicin; D003520:Cyclophosphamide
Supportive Therapie mit xenogenen Peptiden bei Patienten mit metastasiertem Mammakarzinom unter aggressiver Chemotherapie (modifiziertes AC-Schema): Eine prospektive, randomisierte Doppelblindstudie.